The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazaki, K.
Right arrow Articles by Podack, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazaki, K.
Right arrow Articles by Podack, E. R.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 1999, 163: 5178-5182.
Copyright © 1999 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Tumor Secreted Heat Shock-Fusion Protein Elicits CD8 Cells for Rejection1

Koichi Yamazaki, Timmy Nguyen and Eckhard R. Podack2

Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL 33101

The endoplasmic reticulum resident heat shock protein gp96 chaperons peptides, including those derived from tumor Ags, on their way to presentation by MHC class I. Replacement of the endoplasmic reticulum retention signal of gp96 with the Fc portion of murine IgG1 generated a secretory form of gp96, gp96-Ig. Tumor cells secreting gp96-Ig exhibited decreased tumorigenicity and increased immunogenicity in vivo and were rejected after initial growth. Rejection required CD8 T cells during the priming and effector phase. CD4 T cells were not required for rejection in either phase. Carrageenan, a compound known to inactivate macrophages in vivo, did not diminish CD8-mediated tumor rejection. Therefore, immunization with tumors secreting gp96-Ig generates efficient tumor-rejecting CD8 CTL without requirement for CD4 or macrophage help. In contrast, immunization with purified, tumor-derived gp96 or with irradiated tumor cells requires both.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. Robert, T. Ramanayake, G. D. Maniero, H. Morales, and A. S. Chida
Phylogenetic Conservation of Glycoprotein 96 Ability to Interact with CD91 and Facilitate Antigen Cross-Presentation
J. Immunol., March 1, 2008; 180(5): 3176 - 3182.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. W. Graner, R. I. Cumming, and D. D. Bigner
The Heat Shock Response and Chaperones/Heat Shock Proteins in Brain Tumors: Surface Expression, Release, and Possible Immune Consequences
J. Neurosci., October 17, 2007; 27(42): 11214 - 11227.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-L. Chang, Y.-C. Tsai, L. He, T.-C. Wu, and C.-F. Hung
Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70
Cancer Res., October 15, 2007; 67(20): 10047 - 10057.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. A. Phelps and M. N. Neely
SalY of the Streptococcus pyogenes Lantibiotic Locus Is Required for Full Virulence and Intracellular Survival in Macrophages
Infect. Immun., September 1, 2007; 75(9): 4541 - 4551.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Oizumi, N. Strbo, S. Pahwa, V. Deyev, and E. R. Podack
Molecular and Cellular Requirements for Enhanced Antigen Cross-Presentation to CD8 Cytotoxic T Lymphocytes
J. Immunol., August 15, 2007; 179(4): 2310 - 2317.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. M. Han, S. G. Park, B. Liu, B.-J. Park, J. Y. Kim, C. H. Jin, Y. W. Song, Z. Li, and S. Kim
Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein 1/p43 Controls Endoplasmic Reticulum Retention of Heat Shock Protein gp96: Its Pathological Implications in Lupus-Like Autoimmune Diseases
Am. J. Pathol., June 1, 2007; 170(6): 2042 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X.-Y. Wang, H. Arnouk, X. Chen, L. Kazim, E. A. Repasky, and J. R. Subjeck
Extracellular Targeting of Endoplasmic Reticulum Chaperone Glucose-Regulated Protein 170 Enhances Tumor Immunity to a Poorly Immunogenic Melanoma
J. Immunol., August 1, 2006; 177(3): 1543 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. C. Di Paolo, S. Tuve, S. Ni, K. E. Hellstrom, I. Hellstrom, and A. Lieber
Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune Responses
Cancer Res., January 15, 2006; 66(2): 960 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
L. E. Raez, S. Fein, and E. R. Podack
Lung Cancer Immunotherapy
Clin. Med. Res., November 1, 2005; 3(4): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Massa, C. Melani, and M. P. Colombo
Chaperon and Adjuvant Activity of hsp70: Different Natural Killer Requirement for Cross-Priming of Chaperoned and Bystander Antigens
Cancer Res., September 1, 2005; 65(17): 7942 - 7949.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
M. W. Graner and D. D. Bigner
Chaperone proteins and brain tumors: Potential targets and possible therapeutics
Neuro-oncol, July 1, 2005; 7(3): 260 - 278.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
B. Berwin, Y. Delneste, R. V. Lovingood, S. R. Post, and S. V. Pizzo
SREC-I, a Type F Scavenger Receptor, Is an Endocytic Receptor for Calreticulin
J. Biol. Chem., December 3, 2004; 279(49): 51250 - 51257.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Ren, R. Strube, X. Zhang, S.-Y. Chen, and X. F. Huang
Potent Tumor-Specific Immunity Induced by an In vivo Heat Shock Protein-Suicide Gene-Based Tumor Vaccine
Cancer Res., September 15, 2004; 64(18): 6645 - 6651.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. D. H. Doody, J. T. Kovalchin, M. A. Mihalyo, A. T. Hagymasi, C. G. Drake, and A. J. Adler
Glycoprotein 96 Can Chaperone Both MHC Class I- and Class II-Restricted Epitopes for In Vivo Presentation, but Selectively Primes CD8+ T Cell Effector Function
J. Immunol., May 15, 2004; 172(10): 6087 - 6092.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
O. Goldmann, M. Rohde, G. S. Chhatwal, and E. Medina
Role of Macrophages in Host Resistance to Group A Streptococci
Infect. Immun., May 1, 2004; 72(5): 2956 - 2963.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Massa, C. Guiducci, I. Arioli, M. Parenza, M. P. Colombo, and C. Melani
Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70
Cancer Res., February 15, 2004; 64(4): 1502 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Fleischer, B. Schmidt, W. Kastenmuller, D. H. Busch, I. Drexler, G. Sutter, M. Heike, C. Peschel, and H. Bernhard
Melanoma-Reactive Class I-Restricted Cytotoxic T Cell Clones Are Stimulated by Dendritic Cells Loaded with Synthetic Peptides, but Fail to Respond to Dendritic Cells Pulsed with Melanoma-Derived Heat Shock Proteins In Vitro
J. Immunol., January 1, 2004; 172(1): 162 - 169.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Mycko, H. Cwiklinska, J. Szymanski, B. Szymanska, G. Kudla, L. Kilianek, A. Odyniec, C. F. Brosnan, and K. W. Selmaj
Inducible Heat Shock Protein 70 Promotes Myelin Autoantigen Presentation by the HLA Class II
J. Immunol., January 1, 2004; 172(1): 202 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. F. Huang, W. Ren, L. Rollins, P. Pittman, M. Shah, L. Shen, Q. Gu, R. Strube, F. Hu, and S.-Y. Chen
A Broadly Applicable, Personalized Heat Shock Protein-Mediated Oncolytic Tumor Vaccine
Cancer Res., November 1, 2003; 63(21): 7321 - 7329.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Rivoltini, C. Castelli, M. Carrabba, V. Mazzaferro, L. Pilla, V. Huber, J. Coppa, G. Gallino, C. Scheibenbogen, P. Squarcina, et al.
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells
J. Immunol., October 1, 2003; 171(7): 3467 - 3474.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. C. Reed, B. Berwin, J. P. Baker, and C. V. Nicchitta
GRP94/gp96 Elicits ERK Activation in Murine Macrophages: A ROLE FOR ENDOTOXIN CONTAMINATION IN NF-{kappa}B ACTIVATION AND NITRIC OXIDE PRODUCTION
J. Biol. Chem., August 22, 2003; 278(34): 31853 - 31860.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. C. Baker-LePain, M. Sarzotti, T. A. Fields, C.-Y. Li, and C. V. Nicchitta
GRP94 (gp96) and GRP94 N-Terminal Geldanamycin Binding Domain Elicit Tissue Nonrestricted Tumor Suppression
J. Exp. Med., December 2, 2002; 196(11): 1447 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. P. Banerjee, D. S. Vinay, A. Mathew, M. Raje, V. Parekh, D. V. R. Prasad, A. Kumar, D. Mitra, and G. C. Mishra
Evidence That Glycoprotein 96 (B2), a Stress Protein, Functions as a Th2-Specific Costimulatory Molecule
J. Immunol., October 1, 2002; 169(7): 3507 - 3518.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Liu, A. M. DeFilippo, and Z. Li
Overcoming Immune Tolerance to Cancer by Heat Shock Protein Vaccines
Mol. Cancer Ther., October 1, 2002; 1(12): 1147 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Berwin, J. P. Hart, S. V. Pizzo, and C. V. Nicchitta
CD91-Independent Cross-Presentation of GRP94(gp96)-Associated Peptides
J. Immunol., May 1, 2002; 168(9): 4282 - 4286.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Zheng, J. Dai, D. Stoilova, and Z. Li
Cell Surface Targeting of Heat Shock Protein gp96 Induces Dendritic Cell Maturation and Antitumor Immunity
J. Immunol., December 15, 2001; 167(12): 6731 - 6735.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. H. More, M. Breloer, and A. von Bonin
Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells
Int. Immunol., September 1, 2001; 13(9): 1121 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. K. Bishop, S. C. Wood, E. J. Eichwald, and C. G. Orosz
Immunobiology of Allograft Rejection in the Absence of IFN-{{gamma}}: CD8+ Effector Cells Develop Independently of CD4+ Cells and CD40-CD40 Ligand Interactions
J. Immunol., March 1, 2001; 166(5): 3248 - 3255.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.